CClinicalTrials.gg
CompletedNCT06626542Updated Jan 2, 2026

Effect of Intra-session Exercise Modes Sequence on Ventricular Function in Patients With Chronic Heart Failure

An interventional study of resistance and aerobic training exercises in Heart Failure, sponsored by Cairo University. Completed at 1 site in Egypt. Open to male participants aged 55 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2023, registered Jun 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
55 Years to 65 Years
Sex
Male
01

Study summary

The aim of this study was to investigate the effect of intra-session exercise modes sequence on ventricular function in patients with chronic heart failure.

Read the detailed description

Sixty male patients with chronic heart failure will be recruited in this study from National Heart Institute Giza, Egypt. Their ages will be ranged from 55 to 65 years old and they will be randomly divided into three groups as following:

  1. Study group (A) includes 20 patients who will receive intra-session exercise modes sequence of aerobic cardiovascular training (CVT) then resistance training (RT) exercises in addition to routine treatment programme.
  2. Study group (B) includes 20 patients who will receive intra-session exercise modes sequence of resistance training (RT) then aerobic cardiovascular training (CVT) exercises in addition to routine treatment programme.
  3. Control group (C) includes 20 patients who will receive routine treatment programme only.

The exercise training programme for both study groups A and B will be applied once per day, three times per week for 12 consecutive weeks.

Inclusion criteria:

All participated patients will be:

  • Male patients with chronic heart failure and ages from 55 to 65 years old.
  • Class II and class III heart failure according to NYHA classification.
  • HFrEF category with LVEF \<40% as documented by echocardiogram within \<6 months.
  • Receiving the same medical treatment programme for at least 3 months.
  • Having a close level of functional capacity assessed by 6 minute walking test.

Exclusion criteria:

Patients who meet one of the following criteria will be excluded:

  • Uncontrolled atrial fibrillation.
  • Diabetes mellitus.
  • Myocardial infarction or recurrent angina within \<3 months.
  • Patients with chronic chest diseases.
  • Severe stenotic valvular disease.
  • Clinically significant peripheral vascular disease.
  • Exercise-induced angina, ST segment changes or exercise induce AV block.
  • Patients with chronic renal failure.
  • Any cognitive impairment that interferes with prescribed exercise procedures.
  • Musculoskeletal or neurological limitation to physical exercise.

RESEARCH ETHICS

The protocol of this study will be approved by the ethics committee of scientific research at the Faculty of Physical Therapy, Cairo University. The study procedure will be explained in details for every patient before the initial assessment. All patients will be informed about the purpose, nature, and potential risks of the study, and a written informed consent will be obtained before participation in the study. The participants' right confidentiality will be observed strictly.

02

Conditions studied

  • Heart Failure

Browse trials for

03

In context

Heart Failure

5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.

This study's enrollment of 60 is below the median of 72 across 3,736 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Male patients with chronic heart failure and ages from 55 to 65 years old.

    • Class II and class III heart failure according to NYHA classification.
    • HFrEF category with LVEF \<40% as documented by echocardiogram within \<6 months.
    • Receiving the same medical treatment programme for at least 3 months.
    • Having a close level of functional capacity assessed by 6 minute walking test

Exclusion criteria

Exclusion Criteria:

    • Uncontrolled atrial fibrillation.

      • Diabetes mellitus.
      • Myocardial infarction or recurrent angina within \<3 months.
      • Patients with chronic chest diseases.
      • Severe stenotic valvular disease.
      • Clinically significant peripheral vascular disease.
      • Exercise-induced angina, ST segment changes or exercise induce AV block.
      • Patients with chronic renal failure.
      • Any cognitive impairment that interferes with prescribed exercise procedures.
      • Musculoskeletal or neurological limitation to physical exercise.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    sequence of aerobic cardiovascular training (CVT) then resistance training (RT) exercises

    Other: resistance and aerobic training exercises

  • Experimental
    sequence of resistance training (RT) then aerobic cardiovascular training (CVT) exercises

    Other: resistance and aerobic training exercises

  • Other
    control group routine treatment programme only

    Other: resistance and aerobic training exercises

Interventions

  • Otherresistance and aerobic training exercises

    resistance and aerobic training exercises

    Also known as: cardiac rehabilitation

06

What researchers measure

Primary outcomes

  1. Left ventricular ejection fraction

    left ventricular ejection fraction is measured by using echocardiography it is measured in percentage %

    Time frame: 12 weeks

Secondary outcomes

  1. The Minnesota living with heart failure questionnaire (MLWHFQ)

    calculate minnasota living with heart failure questionnaire score 21 item MLHFQ uses a 6-point scale where 0 = no, 1= very little and 5= very much

    Time frame: 12 weeks

  2. Cardiorespiratory fitness 6 minute walk test

    after the test we calculate the distance patient walked in meters and we use this distance to evaluate the cardiopulmonary fitness

    Time frame: 12 weeks

  3. Vo2 Max

    by using distance from the 6MWT in meters we can calculate the vo2 max using specific equation

    Time frame: 12 week

  4. Blood pressure

    blood pressure systolic by using the sphygmomanometer palpatory method - diastolic by using the auscultatory method by sphygmomanometer and stethoscope

    Time frame: 12 weeks

  5. Rate of pressure product

    rate pressure product will be calculated by this equation : patient heart rate \* systolic blood pressure / 1000

    Time frame: 12 week

07

Study locations

1 site
  • National Heart Institute
    Giza, Agouza Giza Governorate 12511, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06626542
Lead sponsor
Cairo University
Responsible party
Yasser Mostafa Mohamed Elhamamsy (Yasser Mostafa Mohamed El-hamamsy, Cairo University) — Principal investigator
First posted
Oct 4, 2024
Start date
Sep 3, 2023
Primary completion
Aug 27, 2025
Completion
Aug 27, 2025
Last update
Jan 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion